Mandate

Vinge advises Blue Wolf Capital Partners in connection with the acquisition of seven manufacturing and development facilities from Recipharm

Vinge has, together with Kirkland & Ellis, advised Blue Wolf Capital Partners LLC (“Blue Wolf”), a middle market private equity firm specializing in the healthcare and industrial sectors, in connection with the acquisition of seven manufacturing and development facilities in Sweden, France, and Spain, from Recipharm Group, a contract development and manufacturing organization (“CDMO”) headquartered in Stockholm.

The seven facilities have been a part of Recipharm for over a decade and have focused on the manufacturing and development of oral solid, semi-solid and liquid dosage form pharmaceutical products. The facilities serve over 120 customers around the world and have a strong track record of quality and regulatory compliance. Together these sites are to form a new independent CDMO platform with continued focus on pharmaceutical manufacturing operating under a new corporate name to be announced after the transaction closes.

Vinge’s team consisted of among other Jonas BergströmMatthias Pannier, Carl Sander, Per Kling and Alexander Rüdén (M&A), Sam Seddigh, Emil Lindwall and Agnes Pigg (Employment), Johan Cederblad, Lina Österberg and Madelene Andersson (Real Estate and Environment) Stojan Arnerstål (Life Science and Regulatory), Mathilda Persson, Fredrika Hjelmberg, Christoffer Nordin, Carla Zachariasson and Elis Allmark (Commercial Contracts and Separation), Daniel WendelssonDavid Olander, Hilda Ivarsson and Hanna Lemne (FDI) and Anna Ekdahl Roos (Transaction Support).

Related

Vinge has advised Sveafastigheter in connection with its uplisting to Nasdaq Stockholm

Vinge has advised Sveafastigheter AB (publ) in connection with its list change from Nasdaq First North Premier Growth Market to Nasdaq Stockholm. The prospectus was published on 13 June 2025 and the trading on Nasdaq Stockholm commenced on 18 June 2025.
June 18, 2025

Vinge advises Bridgepoint in its acquisition of Safe Life

Vinge advises Bridgepoint in its agreement to acquire a significant controlling stake in Safe Life, a global leader in the distribution of automated external defibrillators (AEDs), in a transaction that values the company at c. €500 million.
June 16, 2025

Vinge advises Armada Investment AG on its investment in Studsvik

Armada Investment AG, the Zurich-based entrepreneurial investment firm led by Daniel S. Aegerter, has increased its shareholding in Studsvik to 29.9% of outstanding shares. The investment builds on Armada's initial 9.9% stake acquired in February 2025. The shares of Studsvik are admitted to trading on Nasdaq Stockholm. Armada has invested across the nuclear supply chain for over a decade, with portfolio companies including Oklo, Commonwealth Fusion Systems, Proxima Fusion, Last Energy, and Blykalla.
June 16, 2025